Gapping up
In reaction to strong earnings/guidance: DGLY +15.5%, FORM +2.4%, KFX +1.1%, (also announces acquisition of Softpro GmbH) ZNH +1%, GZT +0.7%.
M&A news: CPWR +15% (WSJ reporting that company is in sale discussions), FLWS +12.6% (signs definitive agreement to acquire Harry & David Holdings for $142.5 mln in cash), TMUS +2.8% (Illiad (ILIAY) in discussions with buyout firms regarding TMUS bid, according to reports), DG +1.7% (to raise bid for FDO for $80/share), TSL +1.4% (acquires Majority Stake in Yunnan Metallurgical New Energy), ARCP +0.8% (confirms Cole Corporate Income Trust entered into merger agreement relating to the sale of CCIT to Select Income REIT (SIR)), FDO +0.6% (Dollar General (DG) confirms enhanced proposal to acquire Family Dollar).
Select pharma/biotech related names showing strength: ELOS +10.5% (still checking), ZGNX +5.9% (reports that Zohydro ER demonstrates sustained 12-hour pain relief), ARNA +3.9% (still checking), NVS +3.5% (new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial, early results of upcoming presentations).
Other news: HGSH +43.2% (signed its second shanty area rebuilding project agreement with a budgeted investment over $750 mln), ASTI +21.2% (announces new common stock investment of $8.0 mln led by largest shareholder), SYNA +4.7% (positive Barron's mention), USG +3.5% (positive Barron's mention), ISNS +2.4% (in sympathy with DGLY), NXPI +2.2% (reports that Apple (AAPL) may partner with Visa (V) and Mastercard (MA) for payment applications), DTV +1.9% (still checking), OWW +1.8% (reaches an agreement with American Airlines (AAL) to continue to offer American Airlines and US Airways (LCC) flights on all of its sites), BLDP +1.8% (appoints Randy MacEwen as President and Chief Executive Officer, effective October 6, 2014), PBA +1.2% (to acquire the Vantage pipeline system and Mistral Midstream's interest in the Saskatchewan Ethane Extraction Plant), NBG +0.9% (still checking), YHOO +0.8% (Alibaba.com to begin roadshow next week, according to reports).
Analyst comments: SPLS +4.9% (upgraded to Outperform from Neutral at Credit Suisse), SD +3.4% (upgraded to Buy at Stifel), CENX +3% (upgraded to Overweight from Equal-Weight at Morgan Stanley), GRPN +2.9% (upgraded to Sector Perform at RBC Capital Mkts), STO +2.9% (upgraded to Buy from Hold at Deutsche Bank), TSLA +2.9% (upgraded to Buy from Hold at Stifel), DSKY+2.6% (initiated with a Overweight at Piper Jaffray), ACHN +2.6% (tgt raised to $15 from $11 at UBS), TS +2.4% (upgraded to Neutral from Sell), RCAP +1.9% (upgraded to Buy from Neutral at Citigroup), ZU +1.5% (upgraded to Buy from Fair Value at CRT Capital), ANET +1.3% (initiated with a Buy at Sun Trust Rbsn Humphrey), COG +1% (upgraded to Buy at Stifel), AAPL +0.8% (target raised to $120 from $105 at Piper Jaffray)
In reaction to strong earnings/guidance: DGLY +15.5%, FORM +2.4%, KFX +1.1%, (also announces acquisition of Softpro GmbH) ZNH +1%, GZT +0.7%.
M&A news: CPWR +15% (WSJ reporting that company is in sale discussions), FLWS +12.6% (signs definitive agreement to acquire Harry & David Holdings for $142.5 mln in cash), TMUS +2.8% (Illiad (ILIAY) in discussions with buyout firms regarding TMUS bid, according to reports), DG +1.7% (to raise bid for FDO for $80/share), TSL +1.4% (acquires Majority Stake in Yunnan Metallurgical New Energy), ARCP +0.8% (confirms Cole Corporate Income Trust entered into merger agreement relating to the sale of CCIT to Select Income REIT (SIR)), FDO +0.6% (Dollar General (DG) confirms enhanced proposal to acquire Family Dollar).
Select pharma/biotech related names showing strength: ELOS +10.5% (still checking), ZGNX +5.9% (reports that Zohydro ER demonstrates sustained 12-hour pain relief), ARNA +3.9% (still checking), NVS +3.5% (new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial, early results of upcoming presentations).
Other news: HGSH +43.2% (signed its second shanty area rebuilding project agreement with a budgeted investment over $750 mln), ASTI +21.2% (announces new common stock investment of $8.0 mln led by largest shareholder), SYNA +4.7% (positive Barron's mention), USG +3.5% (positive Barron's mention), ISNS +2.4% (in sympathy with DGLY), NXPI +2.2% (reports that Apple (AAPL) may partner with Visa (V) and Mastercard (MA) for payment applications), DTV +1.9% (still checking), OWW +1.8% (reaches an agreement with American Airlines (AAL) to continue to offer American Airlines and US Airways (LCC) flights on all of its sites), BLDP +1.8% (appoints Randy MacEwen as President and Chief Executive Officer, effective October 6, 2014), PBA +1.2% (to acquire the Vantage pipeline system and Mistral Midstream's interest in the Saskatchewan Ethane Extraction Plant), NBG +0.9% (still checking), YHOO +0.8% (Alibaba.com to begin roadshow next week, according to reports).
Analyst comments: SPLS +4.9% (upgraded to Outperform from Neutral at Credit Suisse), SD +3.4% (upgraded to Buy at Stifel), CENX +3% (upgraded to Overweight from Equal-Weight at Morgan Stanley), GRPN +2.9% (upgraded to Sector Perform at RBC Capital Mkts), STO +2.9% (upgraded to Buy from Hold at Deutsche Bank), TSLA +2.9% (upgraded to Buy from Hold at Stifel), DSKY+2.6% (initiated with a Overweight at Piper Jaffray), ACHN +2.6% (tgt raised to $15 from $11 at UBS), TS +2.4% (upgraded to Neutral from Sell), RCAP +1.9% (upgraded to Buy from Neutral at Citigroup), ZU +1.5% (upgraded to Buy from Fair Value at CRT Capital), ANET +1.3% (initiated with a Buy at Sun Trust Rbsn Humphrey), COG +1% (upgraded to Buy at Stifel), AAPL +0.8% (target raised to $120 from $105 at Piper Jaffray)